Novartis reports exploding sales in their respiratory treatments - Arikace will never get 10%
Novartis respiratory treatments the podhaler for cystic fibrosis and their Ultibro Breezhaler for COPD are catalysts for future growth Novartis reported today.Although the podhaler is not in the same category as their billion dollar drugs,the cystic fibrosis market along with Glaxo are entrenched.By the time Arikace gets approved it will be a small player.
Some partial answers but Novartis spoke of the ADVANTAGES over competitors on why the sales of the podhaler are EXPLODING and why Insmeds Arikace will be a cystic fibrosis choice on a third tier. The European Union gave the podhaler the FIRST CHOICE among all cf options.The podhaler is portable runs without a charger of electrical outlet and does NOT HAVE TO BE REFRIGERATED ARIKACE MUST BE REFRIGERATED.The podhalers competitive pricing makes it the first choice AROUND THE WORLD.
Dum-Dum, If that were true you would not be posting 24/7. But because of competitive fear, you have no choice. Your transparency as a paid goon is laughable. Arikace will capture 30-40% of the market within a few years because one time allways wins out. And Arikace for NTM should dominate the marketplace. Now put that in your pipe and gag on it.
Dorian. I don't think you realize how true your statements are. For someone to post 24/7 with such an arrogant bent towards the negativity of anything possibly positive for Insmed, and who will NEVER post facts with a footnote, website, or third party validation is nothing more than someone who is an agent for Novartis. Why would anyone spend as much time typing BS all the time unless he is compensated in some form. Anything he puts down is an opinion or subjective. If he was a lawyer, he would never win a case, because he presents no facts. He's a paid LOSER.